Pneumonia

Disclaimer: This information is intended for educational purposes and as a comprehensive clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare provider based on the individual patient's condition, available evidence, and current medical standards. This content is regularly updated but may not reflect the absolute latest developments in every aspect.

Overview

• Definition: Pneumonia is an acute inflammatory condition of the lung parenchyma, primarily affecting the alveoli and causing consolidation, resulting from an infection. It can be caused by bacteria, viruses, fungi, or other microorganisms.
• Epidemiology:
  • Incidence: A leading cause of morbidity and mortality worldwide. In the US, approximately 2-3 million cases of Community-Acquired Pneumonia (CAP) occur annually, with over 500,000 hospitalizations.
  • Mortality: Varies significantly by age, comorbidities, and severity. Mortality for outpatient CAP is <1%, for hospitalized non-ICU CAP is 5-15%, and for ICU CAP can be 25-50%. Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) have higher mortality rates (up to 30-50%).
  • Demographics: Most common in very young children (<5 years) and older adults (≥65 years). Immunocompromised individuals, those with chronic underlying diseases (e.g., COPD, heart failure, diabetes), and smokers are at higher risk.
• Classification:
  • By Acquisition:
    • Community-Acquired Pneumonia (CAP): Acquired outside of hospitals or long-term care facilities.
    • Hospital-Acquired Pneumonia (HAP): Pneumonia developing ≥48 hours after hospital admission, not present at admission.
    • Ventilator-Associated Pneumonia (VAP): A subtype of HAP, developing ≥48 hours after endotracheal intubation.
    • Healthcare-Associated Pneumonia (HCAP): Historically used for patients with extensive healthcare contact (e.g., nursing home residents, recent hospitalization, dialysis). Note: The concept of HCAP has largely been deemphasized in recent guidelines (e.g., 2016 IDSA/ATS HAP/VAP guidelines) due to its poor predictive value for multi-drug resistant (MDR) pathogens; these patients are now often managed based on individual risk factors for MDR organisms.
    • Aspiration Pneumonia: Due to aspiration of oropharyngeal or gastric contents.
  • By Etiology: Bacterial (most common), viral, fungal, parasitic.
  • By Anatomical Pattern (CXR): Lobar, bronchopneumonia, interstitial.
  • By Typical/Atypical Presentation:
    • Typical: Abrupt onset, high fever, productive cough, pleuritic chest pain (e.g., Streptococcus pneumoniae).
    • Atypical: Gradual onset, dry cough, low-grade fever, extrapulmonary symptoms (e.g., Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila).

Pathophysiology

• Mechanism:
  • Infection typically occurs when microorganisms overcome the host's normal defense mechanisms (e.g., mucociliary escalator, cough reflex, alveolar macrophages).
  • Pathogens reach the lower respiratory tract via microaspiration of oropharyngeal secretions (most common), inhalation of aerosols, hematogenous spread, or direct extension.
  • Once in the alveoli, pathogens multiply, triggering an inflammatory response. Neutrophils and other immune cells infiltrate, leading to exudate accumulation in the alveolar spaces, impairing gas exchange (ventilation-perfusion mismatch).
  • This consolidation is visible on imaging and accounts for clinical signs like crackles and dullness to percussion.
• Risk Factors:
  • Host Factors:
    • Age: Extremes of age (<5 years, >65 years).
    • Immunosuppression: HIV/AIDS, organ transplantation, chemotherapy, chronic corticosteroid use, primary immunodeficiencies.
    • Chronic Comorbidities: COPD, asthma, heart failure, diabetes mellitus, chronic kidney disease, liver disease, neurological disorders (stroke, Parkinson's, dementia with dysphagia).
    • Impaired Consciousness/Swallowing: Alcoholism, drug overdose, seizures, stroke, general anesthesia, dysphagia, impaired gag reflex (risk of aspiration).
    • Structural Lung Disease: Bronchiectasis, cystic fibrosis, lung cancer.
  • Lifestyle/Environmental:
    • Smoking: Impairs mucociliary clearance and alveolar macrophage function.
    • Alcohol Abuse: Impairs host defenses, malnutrition, aspiration risk.
    • Exposure: Viral respiratory infections (e.g., influenza, RSV) predispose to bacterial pneumonia. Exposure to contaminated water (Legionella).
  • Healthcare-Related (for HAP/VAP):
    • Hospitalization (especially ICU stay), mechanical ventilation, nasogastric tubes, underlying lung disease, recent surgery, altered mental status, antacid therapy.
• Protective Factors:
  • Intact Host Defenses: Cough reflex, glottic closure, mucociliary clearance, normal microbiota in the upper respiratory tract, effective immune response (alveolar macrophages, humoral and cellular immunity).
  • Vaccinations: Influenza and pneumococcal vaccines.
  • Healthy Lifestyle: Non-smoking, moderate alcohol consumption, good nutrition.
  • Good Oral Hygiene: Reduces pathogenic colonization in the oropharynx.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Cough: Productive (purulent sputum, rust-colored in pneumococcal pneumonia) or non-productive.
  • Fever/Chills: Often abrupt onset, especially with typical bacterial pneumonia.
  • Dyspnea: Shortness of breath, often progressive.
  • Pleuritic Chest Pain: Sharp pain worsening with deep inspiration or cough, indicating pleural involvement.
  • Fatigue/Malaise: General feeling of unwellness.
• Early Signs:
  • Malaise, myalgia, headache (especially with viral or atypical pneumonia).
  • Low-grade fever.
  • Mild cough.
• Advanced Signs:
  • Significant hypoxemia (cyanosis).
  • Severe respiratory distress (tachypnea, accessory muscle use, grunting).
  • Altered mental status (confusion, disorientation), particularly in elderly patients.
  • Signs of sepsis or septic shock (hypotension, tachycardia, poor perfusion).
• Atypical Presentations:
  • Elderly: May present with altered mental status, falls, anorexia, or general weakness without prominent respiratory symptoms or fever. Cough may be mild or absent.
  • Immunocompromised: May have subtle or delayed symptoms, different pathogens (e.g., Pneumocystis jirovecii pneumonia [PJP], fungal infections).
  • Children: Rapid breathing, grunting, nasal flaring, chest indrawing, irritability, poor feeding.

Physical Examination

• Inspection:
  • Respiratory rate: Tachypnea (>20 breaths/min in adults, higher in children).
  • Work of breathing: Use of accessory muscles, nasal flaring, intercostal retractions.
  • Cyanosis: Bluish discoloration of lips, nail beds (indicating hypoxemia).
  • General appearance: Diaphoretic, appearing ill, flushed.
• Palpation:
  • Tactile Fremitus: Increased over areas of consolidation (lobar pneumonia).
  • Tracheal Deviation: Unlikely unless significant pleural effusion or tension pneumothorax complication.
• Percussion:
  • Dullness: Over areas of alveolar consolidation or pleural effusion.
• Auscultation:
  • Crackles (Rales): Fine or coarse, typically heard over the affected lung fields.
  • Bronchial Breath Sounds: Loud, harsh, hollow sounds heard over consolidated lung tissue (where vesicular sounds should be).
  • Egophony: "E" sounds heard as "A" over consolidation.
  • Whispered Pectoriloquy: Whispered words are heard clearly over consolidation.
  • Pleural Friction Rub: May be heard if pleurisy is present.
  • Diminished Breath Sounds: May be heard with large pleural effusions or severe consolidation.

Diagnostic Approach

History Taking

• Key Questions:
  • Symptom Onset and Duration: Acute vs. gradual.
  • Characteristics of Cough: Productive vs. dry, sputum color/amount.
  • Fever/Chills: Presence, degree, pattern.
  • Chest Pain: Pleuritic or non-pleuritic.
  • Dyspnea: At rest, on exertion, progressive?
  • Associated Symptoms: Myalgia, headache, fatigue, GI symptoms (nausea, vomiting, diarrhea - common with Legionella, Mycoplasma).
  • Risk Factors: Smoking, alcohol use, chronic medical conditions (COPD, asthma, CHF, DM, kidney disease, liver disease), immunosuppression.
  • Exposure History: Recent travel, animal exposure, sick contacts, nursing home residence, recent hospitalization, IV drug use, aspiration risk.
  • Vaccination Status: Influenza, pneumococcal.
  • Medications: Especially immunosuppressants.
  • Allergies: Especially to antibiotics.
• Red Flags:
  • Hypotension (Systolic BP <90 mmHg).
  • Tachypnea (>30 breaths/min).
  • Hypoxemia (SpO2 <90% on room air or PaO2/FiO2 ratio <250).
  • Altered mental status (confusion, disorientation).
  • Bilateral infiltrates or multilobar involvement on CXR.
  • Rapid progression of symptoms.
  • Signs of organ dysfunction (e.g., acute kidney injury).

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with differential: Leukocytosis with neutrophilia is common in bacterial pneumonia. Leukopenia can indicate severe sepsis or specific pathogens (e.g., some viral).
  • Basic Metabolic Panel (BMP): Assess renal function, electrolytes (e.g., hyponatremia with Legionella or SIADH).
  • Inflammatory Markers: C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) are non-specific but elevated in infection.
  • Arterial Blood Gas (ABG): For patients with significant dyspnea or hypoxemia, to assess oxygenation and acid-base status.
  • Lactate: To screen for sepsis/septic shock, elevated in tissue hypoperfusion.
• Confirmatory (for specific situations/severe disease):
  • Blood Cultures: Recommended for severe CAP requiring ICU admission, HAP/VAP, or if concern for bacteremia/sepsis. Obtain 2 sets before antibiotics. Yield is low (~5-14% in CAP).
  • Sputum Gram Stain and Culture: Obtain from patients with productive cough, especially severe CAP, HAP/VAP, or those failing empiric therapy. Requires good quality specimen (<10 squamous epithelial cells, >25 PMNs per low power field). Not routinely recommended for outpatient CAP.
  • Urine Antigen Tests:
    • Streptococcus pneumoniae urinary antigen: Recommended for severe CAP. High specificity, variable sensitivity.
    • Legionella pneumophila urinary antigen (serogroup 1): Recommended for severe CAP or if epidemiological risk factors. High specificity.
  • Respiratory Viral Panel (PCR): For influenza, SARS-CoV-2, RSV, adenovirus, parainfluenza, metapneumovirus. Recommended during viral season or pandemic, especially for severe pneumonia or hospitalized patients.
  • Procalcitonin: Can be used to guide discontinuation of antibiotic therapy in patients with respiratory infections, but not to initiate. A level <0.25 ng/mL suggests low likelihood of bacterial infection.
  • Special Pathogen Testing: HIV testing (if risk factors), fungal cultures (if immunocompromised), acid-fast bacilli stain/culture (if TB suspected).
  • Bronchoscopy with Bronchoalveolar Lavage (BAL): Considered for non-responding patients, immunocompromised patients, or when specific pathogens are suspected (e.g., PJP, Nocardia, TB).

Imaging

• Recommended:
  • Chest X-ray (CXR): Posterior-anterior (PA) and Lateral views.
    • Purpose: Essential for diagnosing pneumonia and identifying complications. A new infiltrate is required to diagnose pneumonia.
    • Findings: Lobar consolidation (e.g., S. pneumoniae), patchy infiltrates (bronchopneumonia), interstitial infiltrates (viral, atypical pathogens, PJP), cavitation (e.g., S. aureus, Klebsiella, anaerobes), pleural effusion.
    • Limitations: May be normal in early stages or in dehydrated patients. Can persist for weeks after clinical recovery.
• Advanced:
  • Computed Tomography (CT) of the Chest:
    • Purpose: For complicated cases, if CXR is inconclusive, to differentiate pneumonia from other conditions, to assess for complications (abscess, empyema, bronchiectasis, obstruction), or in immunocompromised patients with unclear CXR findings.
    • Findings: Better delineation of consolidation, ground-glass opacities, nodules, cavitation, pleural effusions.
  • Thoracic Ultrasound: Primarily used to detect and characterize pleural effusions, guide thoracentesis, or identify consolidation at the pleural surface.

Management

Acute Management

• Immediate:
  • Severity Assessment: Utilize validated risk stratification tools like CURB-65 or Pneumonia Severity Index (PSI/PORT score) for CAP.
    • CURB-65: Confusion, Urea >7 mmol/L (19.6 mg/dL), Respiratory rate >30 breaths/min, Blood pressure (systolic <90 mmHg or diastolic ≤60 mmHg), age 65 or older.
      • 0-1 point: Low risk, typically outpatient management.
      • 2 points: Moderate risk, consider inpatient vs. closely observed outpatient.
      • ≥3 points: High risk, typically requires inpatient admission (often ICU for 4-5 points).
    • PSI/PORT Score: More complex, categorizes patients into I-V risk classes. Class IV/V usually requires hospitalization.
  • Oxygen Therapy: Administer oxygen to maintain SpO2 ≥90% (or ≥88% for COPD patients). Nasal cannula, simple mask, non-rebreather mask, high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), or mechanical ventilation if needed.
  • IV Fluids: For patients with hypotension or signs of dehydration.
• Stabilization:
  • Empiric Antibiotic Therapy: Start promptly.
    • CAP:
      • Outpatient (no comorbidities/risk factors for MDR): Amoxicillin 1g TID OR Doxycycline 100mg BID OR Azithromycin 500mg daily (if local macrolide resistance <25%).
      • Outpatient (comorbidities/risk factors or recent antibiotic use): Amoxicillin-clavulanate 875/125mg BID + Macrolide (Azithromycin 500mg daily) OR Respiratory Fluoroquinolone (Levofloxacin 750mg daily or Moxifloxacin 400mg daily).
      • Inpatient, non-ICU: Beta-lactam (e.g., Ceftriaxone 1g daily IV, Cefotaxime 1-2g IV q8h, Ampicillin-Sulbactam 1.5-3g IV q6h) + Macrolide (Azithromycin 500mg IV/PO daily) OR Respiratory Fluoroquinolone (Levofloxacin 750mg IV/PO daily or Moxifloxacin 400mg IV/PO daily).
      • Inpatient, ICU (no risk for Pseudomonas): Beta-lactam + Macrolide OR Beta-lactam + Respiratory Fluoroquinolone.
      • Inpatient, ICU (risk for Pseudomonas): Anti-pseudomonal beta-lactam (e.g., Piperacillin-Tazobactam 4.5g IV q6h, Cefepime 2g IV q8h, Imipenem 500mg IV q6h, Meropenem 1g IV q8h) + Macrolide OR Anti-pseudomonal beta-lactam + Respiratory Fluoroquinolone.
      • Inpatient, ICU (risk for MRSA): Add Vancomycin (15mg/kg IV q12h, target trough 15-20 mcg/mL) or Linezolid (600mg IV/PO q12h).
    • HAP/VAP: Empiric regimen depends on local antibiogram and risk factors for MDR pathogens. Typically involves coverage for Pseudomonas aeruginosa and MRSA.
      • Single agent for Pseudomonas (low risk of MDR): Piperacillin-Tazobactam OR Cefepime OR Levofloxacin OR Imipenem/Meropenem.
      • Dual agents for Pseudomonas (high risk of MDR or high mortality risk): Use two agents from different classes (e.g., Piperacillin-Tazobactam + Ciprofloxacin OR Cefepime + Gentamicin).
      • Add MRSA coverage (if risk factors for MRSA or high MRSA prevalence): Vancomycin OR Linezolid.
  • Corticosteroids: May be considered in severe CAP (e.g., requiring vasopressors) and in patients with CAP and associated severe inflammation. Not routinely recommended for all patients.
• Emergency:
  • ICU Admission: For patients meeting criteria for severe sepsis/septic shock, progressive respiratory failure, need for mechanical ventilation, or multi-organ dysfunction.
  • Early Goal-Directed Therapy: For septic shock (fluid resuscitation, vasopressors, blood cultures, empiric antibiotics within 1 hour).

Chronic Management

• Pharmacological:
  • Duration of Antibiotic Therapy:
    • Uncomplicated CAP: Minimum 5 days, or until afebrile for 48-72 hours, and clinically stable (no more than one CAP-associated sign of instability: temperature >37.8°C, HR >100 bpm, RR >24 breaths/min, SBP <90 mmHg, SpO2 <90%).
    • HAP/VAP: Typically 7 days, but can be longer (10-14 days) for specific pathogens or complicated cases.
    • Aspiration Pneumonia: Often treated for 5-7 days.
  • De-escalation: Once culture results are available and patient is improving, narrow the antibiotic spectrum to target specific pathogen(s) and resistance patterns.
  • Antiviral Therapy: If influenza is suspected/confirmed (e.g., Oseltamivir 75mg BID for 5 days), start within 48 hours of symptom onset for maximal benefit.
  • Antifungal Therapy: If fungal pneumonia is diagnosed (e.g., with specific risk factors like immunosuppression).
• Non-pharmacological:
  • Supportive Care: Hydration, nutritional support, rest.
  • Pulmonary Hygiene: Deep breathing exercises, incentive spirometry, early ambulation to prevent atelectasis and improve lung function.
  • Smoking Cessation: Crucial for recovery and prevention of future episodes.
  • Physical Therapy/Rehabilitation: For patients with prolonged hospitalization or deconditioning.
• Monitoring:
  • Clinical Status: Daily assessment of vital signs, oxygen saturation, mental status, cough, sputum production.
  • Inflammatory Markers: CRP or procalcitonin can trend downwards with effective treatment. Not mandatory but can aid in antibiotic discontinuation.
  • Chest X-ray: Not routinely repeated unless clinical deterioration or failure to improve. Radiographic resolution often lags behind clinical improvement.

Treatment Algorithms

• First-Line (Empiric):
  • Assess Severity (CURB-65/PSI) -> Determine Outpatient/Inpatient/ICU.
  • Outpatient: Amoxicillin/Doxycycline/Macrolide (if no comorbidities) OR Amoxicillin-Clavulanate + Macrolide/Respiratory Fluoroquinolone (if comorbidities/risk factors).
  • Inpatient, non-ICU: Beta-lactam + Macrolide OR Respiratory Fluoroquinolone.
  • Inpatient, ICU: Beta-lactam + Macrolide (add MRSA/Pseudomonas coverage if risk factors).
  • HAP/VAP: Empiric broad-spectrum antibiotics covering common MDR pathogens based on local resistance patterns and risk factors (anti-pseudomonal + anti-MRSA).
• Second-Line (After 48-72 hours if no improvement or cultures return):
  • Re-evaluate Diagnosis: Consider non-infectious causes (pulmonary embolism, heart failure, drug reaction, organizing pneumonia), or atypical infections.
  • Broaden Empiric Coverage: If initial antibiotics were too narrow, consider adding agents for MRSA, Pseudomonas, or anaerobes.
  • Switch to Targeted Therapy: Based on sputum/blood culture results and susceptibilities (de-escalate).
  • Consider Imaging: CT scan for better anatomical detail or to rule out complications.
• Refractory Cases (No improvement after 3-5 days of appropriate therapy):
  • Rule out Non-Infectious Causes: Pulmonary embolism, heart failure, ARDS, drug-induced lung injury, organizing pneumonia, malignancy.
  • Re-evaluate Antimicrobial Therapy: Is the dose adequate? Is there drug penetration to the site of infection? Is the organism truly susceptible? Any drug interactions?
  • Consider Less Common Pathogens: Fungi, mycobacteria (TB), viruses not covered by initial panel, Nocardia, endemic fungi.
  • Diagnostic Procedures: Bronchoscopy with BAL, bronchoalveolar lavage, or transbronchial biopsy for definitive pathogen identification and to rule out other lung diseases. Thoracentesis for pleural effusion.
  • Surgical Intervention: For empyema (chest tube drainage, decortication), lung abscess (rarely).

Complications

• Common:
  • Pleural Effusion: Accumulation of fluid in the pleural space (parapneumonic effusion). Can be sterile (simple) or infected (complicated effusion/empyema).
  • Empyema: Pus in the pleural space, requiring drainage (chest tube, fibrinolytics, or surgical decortication).
  • Lung Abscess: Localized collection of pus in the lung parenchyma, usually from aspiration or virulent bacteria (S. aureus, Klebsiella, anaerobes).
  • Bacteremia/Sepsis: Spread of infection to the bloodstream, leading to systemic inflammatory response syndrome (SIRS), sepsis, septic shock, and multi-organ dysfunction.
  • Respiratory Failure: Requiring mechanical ventilation.
• Serious:
  • Acute Respiratory Distress Syndrome (ARDS): Severe inflammatory lung injury leading to profound hypoxemia.
  • Septic Shock: Life-threatening organ dysfunction caused by a dysregulated host response to infection.
  • Multi-Organ Failure: Including acute kidney injury, liver dysfunction, disseminated intravascular coagulation (DIC).
  • Pericarditis/Myocarditis: Inflammation of the heart lining or muscle.
  • Endocarditis: Infection of heart valves (rare).
  • Meningitis: Spread of infection to the meninges (especially S. pneumoniae).
• Long-term:
  • Post-pneumonia Fatigue: Prolonged weakness and fatigue post-recovery.
  • Bronchiectasis: Permanent dilation of airways, rarely a direct consequence but can be exacerbated by severe pneumonia.
  • Lung Scarring/Fibrosis: Can occur after severe or recurrent pneumonia, potentially leading to restrictive lung disease or impaired function.

Prognosis

• Factors:
  • Severity of Illness: As assessed by CURB-65 or PSI (higher scores predict worse outcomes).
  • Age: Extremes of age (very young and very old) are associated with higher mortality.
  • Comorbidities: Number and severity of underlying chronic diseases (e.g., heart failure, COPD, diabetes, renal failure, liver disease, immunosuppression).
  • Causative Organism: Certain pathogens (e.g., S. aureus, P. aeruginosa, resistant bacteria) are associated with worse outcomes.
  • Timeliness and Appropriateness of Treatment: Early initiation of appropriate antibiotics improves prognosis.
  • Presence of Complications: Development of empyema, ARDS, sepsis significantly worsens prognosis.
• Survival:
  • Overall Mortality (CAP): ~1-3% for outpatients, 5-15% for hospitalized non-ICU patients, 25-50% for ICU patients.
  • HAP/VAP Mortality: Often higher, ranging from 10-50% depending on risk factors and pathogen.
• Quality of Life:
  • Recovery can be prolonged, especially in older adults or those with severe disease.
  • Patients may experience persistent fatigue, dyspnea on exertion, and reduced functional capacity for weeks to months after discharge.
  • Impact on pre-existing comorbidities (e.g., worsening heart failure exacerbations).

Prevention

• Primary: Preventing initial occurrence.
  • Vaccinations:
    • Influenza Vaccine: Annually for all individuals ≥6 months of age. Reduces risk of influenza and subsequent bacterial pneumonia.
    • Pneumococcal Vaccines:
      • PCV13 (Prevnar 13®): Recommended for all children. For adults ≥65 years not previously vaccinated with PCV13, and for individuals aged 19-64 with certain medical conditions (e.g., immunocompromised, CSF leak, cochlear implant).
      • PPSV23 (Pneumovax 23®): Recommended for all adults ≥65 years. Also for individuals aged 19-64 with certain medical conditions (e.g., chronic heart/lung disease, diabetes, smokers, chronic liver disease).
      • PCV15 (Vaxneuvance®) and PCV20 (Prevnar 20®): Newer options providing broader coverage. PCV20 can be used as a single vaccine for adults ≥18 years. If PCV15 is used, followed by PPSV23.
  • Smoking Cessation: Reduces risk significantly.
  • Alcohol Moderation: Reduces aspiration risk and improves immune function.
  • Hand Hygiene: Frequent hand washing to reduce transmission of respiratory pathogens.
  • Management of Chronic Conditions: Optimal control of conditions like diabetes, heart failure, and COPD.
  • Aspiration Precautions: Elevate head of bed, dysphagia assessment and appropriate diet modifications, good oral hygiene.
  • Infection Control: For HAP/VAP: Head of bed elevation (30-45 degrees), daily sedation vacations, spontaneous breathing trials, oral care with chlorhexidine, DVT prophylaxis, stress ulcer prophylaxis.
• Secondary: Early detection and intervention.
  • Prompt diagnosis and initiation of appropriate antibiotics upon recognition of symptoms.
  • Early recognition of deteriorating status and transfer to higher level of care (e.g., ICU).
• Tertiary: Preventing complications and recurrence.
  • Adherence to full course of antibiotics.
  • Pulmonary rehabilitation and follow-up for patients with severe disease.
  • Addressing underlying comorbidities that increase risk.

Special Populations

• Pediatric:
  • Etiology: Viruses (RSV, influenza, adenovirus, parainfluenza) are more common than bacteria, especially in infants. S. pneumoniae, H. influenzae, Mycoplasma pneumoniae are common bacterial causes.
  • Presentation: May be non-specific in infants (irritability, poor feeding, lethargy, grunting, nasal flaring, tachypnea, chest indrawing). Older children more typically present with fever, cough, dyspnea.
  • Diagnosis: Clinical assessment often sufficient; CXR for moderate-severe cases. Viral testing increasingly common.
  • Treatment: Amoxicillin is first-line for suspected bacterial CAP. Macrolides for atypical pathogens (older children). Avoid tetracyclines in young children. Oxygen support, IV fluids if needed.
• Geriatric:
  • Presentation: Often atypical (altered mental status, falls, anorexia, generalized weakness, functional decline) with minimal or absent cough/fever.
  • Increased Severity: Higher risk of severe disease, complications, and mortality due to reduced physiological reserve, comorbidities, and often delayed presentation.
  • Diagnosis: May be challenging due to atypical presentation. Lower threshold for CXR.
  • Treatment: Similar antibiotics but careful with dosing due to renal/hepatic impairment. Increased risk of drug interactions and adverse effects. Early mobilization and supportive care are crucial.
• Pregnancy:
  • Diagnosis: CXR with abdominal shielding generally considered safe. Avoid or limit unnecessary radiation exposure.
  • Treatment: Choose antibiotics safe in pregnancy.
    • Safe: Beta-lactams (penicillins, cephalosporins), macrolides (azithromycin is preferred, erythromycin/clarithromycin less so due to GI side effects/data).
    • Avoid/Caution: Fluoroquinolones (cartilage damage in animal studies), tetracyclines (dental discoloration, bone effects), trimethoprim-sulfamethoxazole (folate antagonist, kernicterus risk near term).
  • Physiological Changes: Pregnancy alters respiratory physiology (increased oxygen consumption, diaphragmatic elevation), potentially increasing dyspnea and susceptibility.
• Comorbidities:
  • Immunocompromised:
    • Etiology: Broader spectrum of pathogens including opportunistic infections (e.g., Pneumocystis jirovecii, fungi like Aspergillus, Cytomegalovirus, Nocardia, mycobacteria).
    • Diagnosis: High suspicion for unusual pathogens. May require specific stains, cultures, PCR, bronchoscopy.
    • Treatment: Empiric broad-spectrum often needed, often with specific anti-opportunistic agents (e.g., Trimethoprim-Sulfamethoxazole for PJP).
  • COPD/Asthma: Higher risk of pneumonia, often with more severe course. Pneumonia can trigger COPD/asthma exacerbation. May need higher oxygen flow.
  • Heart Failure: Symptoms can mimic pneumonia (dyspnea, cough, crackles). CXR crucial to differentiate. Co-management of both conditions.
  • Diabetes Mellitus: Increased risk of bacterial infections, especially S. pneumoniae and S. aureus. Worse outcomes.
  • Chronic Kidney Disease/End-Stage Renal Disease: Increased risk of infection, altered drug clearance requiring dose adjustments.

Clinical Pearls

• Diagnostic:
  • CXR is key: A new infiltrate on CXR is essential for the diagnosis of pneumonia. However, in early stages or dehydration, CXR can be negative. Re-image in 12-24 hours if high suspicion.
  • Don't forget Atypical organisms: Consider Mycoplasma, Chlamydophila, Legionella in patients with dry cough, milder symptoms, or extrapulmonary features.
  • Procalcitonin for stewardship: Useful for guiding antibiotic discontinuation, not necessarily initiation. Levels <0.1-0.25 ng/mL suggest low likelihood of bacterial infection.
  • Severity scores matter: Use CURB-65 or PSI to guide disposition and initial empiric therapy.
• Treatment:
  • Timely antibiotics: Start empiric antibiotics as soon as possible after diagnosis, especially for hospitalized patients or severe cases.
  • Source control for complications: Empyema, lung abscess, or necrotic pneumonia may require drainage or surgical intervention in addition to antibiotics.
  • Fluid management: Be judicious with IV fluids, especially in elderly or those with heart failure, to avoid fluid overload and worsening respiratory compromise.
  • De-escalation: Once culture results are available and patient is improving, narrow the antibiotic spectrum to minimize resistance and side effects.
  • Duration: Shorter courses (5-7 days) are often sufficient for uncomplicated CAP, avoiding prolonged antibiotic exposure.
• Pitfalls:
  • Misdiagnosis: Attributing all cough/fever to pneumonia; not considering other causes (e.g., acute bronchitis, heart failure exacerbation, PE, malignancy).
  • Delayed antibiotics: Failing to initiate empiric antibiotics promptly, especially in severe cases.
  • Inadequate coverage: Not covering common or resistant pathogens, particularly in HAP/VAP or immunocompromised patients.
  • Over-reliance on CXR resolution: Radiographic resolution lags behind clinical improvement; repeating CXR too frequently without clinical indication is usually not helpful.
  • Not addressing underlying risk factors: Failing to encourage smoking cessation, assess for dysphagia, or ensure vaccination status.

Recent Updates

• Guidelines:
  • 2019 ATS/IDSA Guidelines for the Management of Community-Acquired Pneumonia in Adults: Key updates include:
    • Recommendations against routine empiric MRSA or Pseudomonas aeruginosa coverage for CAP unless specific risk factors are present.
    • Stronger recommendations for outpatient vs. inpatient management using validated scores.
    • Recommending against routine follow-up CXRs unless clinical deterioration or specific indications.
    • Conditional recommendation for corticosteroids in severe CAP with septic shock.
  • 2016 ATS/IDSA Guidelines for the Management of Adults with Hospital-Acquired and Ventilator-Associated Pneumonia:
    • De-emphasis of HCAP as a distinct entity for guiding empiric MDR coverage, instead focusing on individual risk factors.
    • Recommendations for empiric antibiotic choices based on risk factors for MDR pathogens.
    • Shorter duration of therapy (7 days) for most HAP/VAP cases.
• Evidence:
  • Procalcitonin-guided antibiotic stewardship: Further studies reinforce its utility in reducing antibiotic exposure and duration in respiratory infections, without compromising outcomes.
  • Role of Corticosteroids: Meta-analyses continue to support a modest benefit (reduced mortality, shorter ICU stay, shorter hospital stay) in severe CAP, particularly those requiring vasopressors. Not routinely recommended for all CAP.
  • Impact of SARS-CoV-2 (COVID-19): The pandemic has highlighted viral pneumonia and its associated complications (ARDS, secondary bacterial infections). It has also influenced diagnostic algorithms and antibiotic stewardship efforts.
• Controversies:
  • Optimal Duration of Antibiotic Therapy: Ongoing debate for certain populations/pathogens; trending towards shorter courses when clinically feasible.
  • Role of Biomarkers: While procalcitonin is established for de-escalation, the utility of other biomarkers (e.g., CRP kinetic, presepsin) in guiding initial therapy or predicting outcomes is still being explored.
  • Empiric MRSA/Pseudomonas Coverage: Balancing the need for broad coverage in severe cases with the imperative for antibiotic stewardship and resistance prevention remains a challenge.

Key References

• Guidelines:
  • Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67.
  • Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 1;63(5):e61-e111.
  • National Institute for Health and Care Excellence (NICE). Pneumonia: diagnosis and management of community- and hospital-acquired pneumonia in adults. NICE guideline [NG138]. Published 2019 Dec 2; last updated 2024 Apr 24.
• Studies:
  • Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243-50. (PSI/PORT score)
  • Lim WS, van der Eerden MM, Laing J, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377-82. (CURB-65 score)
  • Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med. 2023 Mar 23;388(25):1931-1941.
• Reviews:
  • Mandell LA, Niederman MS. Aspiration Pneumonia. N Engl J Med. 2019 Jan 31;380(7):651-663.
  • Ramirez JA, Wiemken RA, Peyrani P, et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Outcomes. Chest. 2008 Nov;134(5):1018-23.